Investors Business Daily
11 Dec 2025, 18:49 UTC · 40w ago
Verdict
Headline leans bullish. We score RYTM +0.90 across two claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.90strongly bullish
What the story claims
2 claims · scored −1 bearish … +1 bullish
Rhythm Pharmaceuticals (RYTM) is initiating registrational testing for its drug setmelanotide to treat Prader-Willi patients.
More positive than 91% of claims this week
European regulators have unexpectedly recommended the approval of Acadia's Rett syndrome drug, Daybu.
Continue reading
5 related stories
More positive than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 84% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
Surged after announcing registrational testing for its leading drug for Prader-Willi patients.
More positive than 86% of ticker scores this week
Stock popped following unexpected recommendations for approval of its Rett syndrome drug in Europe.
More positive than 86% of ticker scores this week
Stock popped to a record high and led a group onto best stock lists.
More positive than 74% of ticker scores this week
Mentioned as leading stocks near buy points with roaring growth.
More positive than 74% of ticker scores this week
Mentioned as leading stocks near buy points with roaring growth.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
1d ago
−6.7%
Price is moving against the score
$97.71 vs $104.77 close before publication (Dec 10) · not market-adjusted
RYTM chart →
